Historical Valuation
MaxCyte Inc (MXCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.49 is considered Undervalued compared with the five-year average of -16.45. The fair price of MaxCyte Inc (MXCT) is between 6.99 to 10.98 according to relative valuation methord. Compared to the current price of 1.43 USD , MaxCyte Inc is Undervalued By 79.55%.
Relative Value
Fair Zone
6.99-10.98
Current Price：1.43
79.55%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
MaxCyte Inc (MXCT) has a current Price-to-Book (P/B) ratio of 0.92. Compared to its 3-year average P/B ratio of 1.69 , the current P/B ratio is approximately -45.89% higher. Relative to its 5-year average P/B ratio of 2.56, the current P/B ratio is about -64.20% higher. MaxCyte Inc (MXCT) has a Forward Free Cash Flow (FCF) yield of approximately -24.93%. Compared to its 3-year average FCF yield of -9.80%, the current FCF yield is approximately 154.48% lower. Relative to its 5-year average FCF yield of -7.52% , the current FCF yield is about 231.54% lower.
P/B
Median3y
1.69
Median5y
2.56
FCF Yield
Median3y
-9.80
Median5y
-7.52
Competitors Valuation Multiple
AI Analysis for MXCT
The average P/S ratio for MXCT competitors is 79.61, providing a benchmark for relative valuation. MaxCyte Inc Corp (MXCT.O) exhibits a P/S ratio of 4.49, which is -94.37% above the industry average. Given its robust revenue growth of -16.35%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MXCT
1Y
3Y
5Y
Market capitalization of MXCT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MXCT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MXCT currently overvalued or undervalued?
MaxCyte Inc (MXCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.49 is considered Undervalued compared with the five-year average of -16.45. The fair price of MaxCyte Inc (MXCT) is between 6.99 to 10.98 according to relative valuation methord. Compared to the current price of 1.43 USD , MaxCyte Inc is Undervalued By 79.55% .
What is MaxCyte Inc (MXCT) fair value?
MXCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MaxCyte Inc (MXCT) is between 6.99 to 10.98 according to relative valuation methord.
How does MXCT's valuation metrics compare to the industry average?
The average P/S ratio for MXCT's competitors is 79.61, providing a benchmark for relative valuation. MaxCyte Inc Corp (MXCT) exhibits a P/S ratio of 4.49, which is -94.37% above the industry average. Given its robust revenue growth of -16.35%, this premium appears unsustainable.
What is the current P/B ratio for MaxCyte Inc (MXCT) as of Jan 10 2026?
As of Jan 10 2026, MaxCyte Inc (MXCT) has a P/B ratio of 0.92. This indicates that the market values MXCT at 0.92 times its book value.
What is the current FCF Yield for MaxCyte Inc (MXCT) as of Jan 10 2026?
As of Jan 10 2026, MaxCyte Inc (MXCT) has a FCF Yield of -24.93%. This means that for every dollar of MaxCyte Inc’s market capitalization, the company generates -24.93 cents in free cash flow.
What is the current Forward P/E ratio for MaxCyte Inc (MXCT) as of Jan 10 2026?
As of Jan 10 2026, MaxCyte Inc (MXCT) has a Forward P/E ratio of -6.04. This means the market is willing to pay $-6.04 for every dollar of MaxCyte Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MaxCyte Inc (MXCT) as of Jan 10 2026?
As of Jan 10 2026, MaxCyte Inc (MXCT) has a Forward P/S ratio of 4.49. This means the market is valuing MXCT at $4.49 for every dollar of expected revenue over the next 12 months.